Close Menu
WashingtonExec
    Podcast Episodes
    LinkedIn Facebook X (Twitter) Instagram YouTube
    LinkedIn Facebook X (Twitter) Instagram YouTube
    WashingtonExec
    Subscribe To The Daily
    • News & Headlines
    • Executive Councils
    • Videos
    • Podcast
    • Events
      • 🏆 Chief Officer Awards
      • 🏆 Pinnacle Awards
    • About
    • Contact Us
    LinkedIn YouTube X (Twitter)
    WashingtonExec
    You are at:Home»News»Contract Awards»Dovel Technologies Secures 2 Biologics Surveillance IDIQs from FDA
    Contract Awards

    Dovel Technologies Secures 2 Biologics Surveillance IDIQs from FDA

    By WashingtonExec Staff WriterNovember 5, 2018
    Share
    LinkedIn Facebook Twitter Email
    Damon Griggs, Dovel Technologies
    Damon Griggs, Dovel Technologies

    Dovel Technologies has won two contracts from the Food and Drug Administration’s Center for Biologics Effectiveness and Research to help build an ecosystem of tools to support biologic product safety.

    Dovel has been awarded under two separate 5-year indefinite-delivery, indefinite-quantity deals: one for data, tools and infrastructure for surveillance of biologics and one covering the development of new and innovative methods for automated reporting for CBER-regulated biological products.

    Dovel secured one of four awards for each of the IDIQs. Each award has a ceiling of $75 million.

    “We are excited to get to work helping build the data strategy and tools that will enhance CBER’s efficiency in meeting their mission to assure the safety and efficacy of biologic products,” said Damon Griggs, Dovel president and chief operating officer. “Our team has exciting and innovative approaches and solutions for data science and automation using machine learning, natural language processing, and more to meet the needs of CBER.”

    The center’s Biologics Effectiveness and Safety, or BEST, initiative aims to expand and enhance current capabilities with respect to data sources, infrastructure, methods and tools and to conduct active surveillance, epidemiologic studies and automated reporting to improve the the safety and efficacy of biologic products including vaccines, blood and blood products, tissues, and advanced therapeutics.

    Related: Dovel Technologies to Update Federal Grants Management System

    Previous ArticleRigil Corp. Picks Up $33.5M FAA Deal
    Next Article Top AI Execs to Watch: Balan Ayyar, Percipient.ai

    Related Posts

    2025 Chief Officer Awards Winner: Amentum’s Travis Johnson

    Top Health Care Execs to Watch in 2025: Booz Allen Hamilton’s Dr. Roman Salasznyk

    WATCH: Harnessing AI in Process Intelligence for Government Efficiency with Appian’s Jason Adolf

    Comments are closed.

    LinkedIn Follow Button LinkedIn Logo Follow Us on LinkedIn
    2025 Chief Officer Awards - Winners Revealed
    Latest Industry Leaders

    Top Cyber Execs to Watch in 2025

    Top Chief Technology Officers to Watch in 2025

    Load More
    Latest Posts

    2025 Chief Officer Awards Winner: Amentum’s Travis Johnson

    June 16, 2025

    Top Health Care Execs to Watch in 2025: Booz Allen Hamilton’s Dr. Roman Salasznyk

    June 16, 2025

    WATCH: Harnessing AI in Process Intelligence for Government Efficiency with Appian’s Jason Adolf

    June 16, 2025

    Top Health Care Execs to Watch in 2025: Acentra Health’s Dr. Ryan Bosch

    June 16, 2025

    Lucy Martin Leads PingWind’s Strategic Shift Toward Mid-Tier Growth & Emerging Tech

    June 15, 2025
    Quick Links
    • Executive Councils & Committees
    • Chief Officer Awards
    • Pinnacle Awards
    • Advertise With Us
    • About WashingtonExec
    • Contact
    Connect
    • LinkedIn
    • YouTube
    • Facebook
    • Twitter

    Subscribe to The Daily

    Connect. Inform. Celebrate.

    Copyright 2023 © WashingtonExec, Inc. | All Rights Reserved. Powered by J Media Group

    Type above and press Enter to search. Press Esc to cancel.